Harmony Biosciences Holdings Inc (HRMY)
34.07
+0.84
(+2.53%)
USD |
NASDAQ |
Nov 22, 16:00
34.07
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Revenue (Quarterly): 186.04M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 186.04M |
June 30, 2024 | 172.81M |
March 31, 2024 | 154.62M |
December 31, 2023 | 168.41M |
September 30, 2023 | 160.27M |
June 30, 2023 | 134.22M |
March 31, 2023 | 119.13M |
December 31, 2022 | 128.31M |
September 30, 2022 | 117.21M |
June 30, 2022 | 107.03M |
Date | Value |
---|---|
March 31, 2022 | 85.31M |
December 31, 2021 | 91.21M |
September 30, 2021 | 80.73M |
June 30, 2021 | 73.82M |
March 31, 2021 | 59.67M |
December 31, 2020 | 56.29M |
September 30, 2020 | 45.61M |
June 30, 2020 | 38.00M |
March 31, 2020 | 19.84M |
December 31, 2019 | 5.995M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.995M
Minimum
Dec 2019
186.04M
Maximum
Sep 2024
100.23M
Average
99.12M
Median
Revenue (Quarterly) Benchmarks
Regeneron Pharmaceuticals Inc | 3.721B |
Incyte Corp | 1.138B |
EyePoint Pharmaceuticals Inc | 10.52M |
Cassava Sciences Inc | -- |
Capricor Therapeutics Inc | 2.262M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 46.09M |
Total Expenses (Quarterly) | 124.33M |
EPS Diluted (Quarterly) | 0.79 |
Enterprise Value | 1.715B |
Gross Profit Margin (Quarterly) | 77.01% |
Profit Margin (Quarterly) | 24.78% |
Earnings Yield | 6.19% |
Operating Earnings Yield | 8.87% |
Normalized Earnings Yield | 6.193 |